Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-08 |
2024-03 |
-14.1 |
-9.95 |
4.15 |
29.43% |
2024-04-04 |
2023-12 |
0 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-31.72 |
-22.03 |
9.69 |
30.55% |
2023-08-10 |
2023-06 |
-49.34 |
-54.19 |
-4.85 |
-9.83% |
2023-05-11 |
2023-03 |
-52.42 |
11.45 |
63.87 |
121.84% |
2023-03-30 |
2022-12 |
-1.53 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-05-12 |
Piper Sandler |
Upgrade |
|
Overweight |
2021-05-27 |
Roth Capital |
Upgrade |
|
Buy |
2020-11-10 |
Piper Sandler |
Upgrade |
|
Overweight |
2018-04-10 |
Roth Capital |
Upgrade |
|
Buy |
2016-09-08 |
Piper Sandler |
Upgrade |
|
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2023-08-08 |
ABDUN-NABI DANIEL J |
Director |
8.34K |
Conversion of Exercise of derivative security |
2023-08-08 |
GRANT GRADY III |
Director |
4.88K |
Conversion of Exercise of derivative security |
2023-08-08 |
HARSANYI ZSOLT |
Director |
8.48K |
Conversion of Exercise of derivative security |
2023-08-08 |
KUNZ BARBARA LOPEZ |
Director |
4.88K |
Conversion of Exercise of derivative security |
2023-08-07 |
KWON SOYOUNG |
Officer |
16.71K |
Conversion of Exercise of derivative security |
2024-01-25 |
LAMOTHE JEFFREY G |
Officer |
28.34K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Cantor Fitzgerald, L. P. |
251.12K |
366.64K |
2.18% |
2023-06-29 |
Vanguard Group Inc |
228.82K |
334.08K |
1.99% |
2023-06-29 |
Schonfeld Strategic Advisors Llc |
144.60K |
211.12K |
1.25% |
2023-06-29 |
Renaissance Technologies, LLC |
80.19K |
117.07K |
0.70% |
2023-06-29 |
Geode Capital Management, LLC |
52.83K |
77.12K |
0.46% |
2023-06-29 |
Blackrock Inc. |
48.05K |
70.15K |
0.42% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
158.48K |
231.37K |
1.38% |
2023-06-29 |
Vanguard Extended Market Index Fund |
70.35K |
102.71K |
0.61% |
2023-06-29 |
Price (T.Rowe) Total Equity Market Index Fund |
46.20K |
67.45K |
0.40% |
2023-05-30 |
Fidelity Extended Market Index Fund |
32.15K |
50.16K |
0.28% |
2023-06-29 |
Legg Mason Global Asset Mgt Tr-Franklin U.S. Small Cap Equity Fd |
10.29K |
15.02K |
0.09% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
7.52K |
11.74K |
0.07% |
Split |
Date |
1 : 44 |
2024-03-06 |
1 : 14 |
2020-03-27 |